EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AxoGen, Inc. – AXGN
To join the AxoGen class action, go to https://www.rosenlegal.com/cases-1478.html or call Phillip Kim, Esq.
Rosen Law Firm, a global investor rights law firm, announces the filing
of a class action lawsuit on behalf of purchasers of the securities of
AxoGen, Inc. (NASDAQ: AXGN): (1) pursuant and/or traceable to the false
and/or misleading registration statement and prospectus issued in
connection with AxoGen’s November 2017 secondary public offering; and/or
(2) purchased or otherwise acquired AxoGen securities pursuant and/or
traceable to AxoGen’s false and/or misleading registration statement and
prospectus issued in connection with AxoGen’s May 2018 secondary public
offering; and/or (3) purchased or otherwise acquired AxoGen securities
between August 7, 2017 and December 18, 2018, inclusive (the “Class
Period”). The lawsuit seeks to recover damages for AxoGen investors
under the federal securities laws.
To join the AxoGen class action, go to https://www.rosenlegal.com/cases-1478.html
or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at
866-767-3653 or email [email protected]
or [email protected]
for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS
CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU
MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS
MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN
ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD
PLAINTIFF.
According to the lawsuit, defendants throughout the Class Period made
false and/or misleading statements and/or failed to disclose that: (1)
AxoGen aggressively increased prices to mask lower sales; (2) AxoGen’s
pricing alienated customers and AxoGen’s future growth; (3) ambulatory
surgery centers form a significant part of the market for AxoGen’s
products; (4) such centers were especially sensitive to price increases;
(5) AxoGen was dependent on a small number of surgeons whom AxoGen paid
to generate sales; (6) AxoGen’s consignment model for inventory was
reasonably likely to lead to channel stuffing; (7) AxoGen offered
purchase incentives to sales representatives to encourage channel
stuffing; (8) AxoGen’s sales representatives were encouraged to backdate
revenue to artificially inflate metrics; (9) AxoGen lacked adequate
internal controls to prevent such channel stuffing and backdating of
revenue; (10) AxoGen’s key operating metrics, such as number of active
accounts, were overstated; and (11) as a result of the foregoing,
defendants’ positive statements about AxoGen’s business, operations, and
prospects, were materially misleading and/or lacked a reasonable basis.
When the true details entered the market, the lawsuit claims that
investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as
lead plaintiff, you must move the Court no later than March 11, 2019. A
lead plaintiff is a representative party acting on behalf of other class
members in directing the litigation. If you wish to join the litigation,
go to https://www.rosenlegal.com/cases-1478.html
or to discuss your rights or interests regarding this class action,
please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law
Firm toll free at 866-767-3653 or via e-mail at [email protected]
or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm,
on Twitter: https://twitter.com/rosen_firm
or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class
Action Services for number of securities class action settlements in
2017. The firm has been ranked in the top 3 each year since 2013.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190212005907/en/